Answers are grounded in this paper and cite their sources.
When managing an older patient with untreated acute myeloid leukemia (AML), my primary goal is to determine whether standard treatment, investigational treatment, or palliative care is most appropriate. “Standard therapy” includes remission induction regimens, commonly referred to as “3 +
No takes yet. Share an insight, caveat, or question.
Elihu H. Estey (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: